83 related articles for article (PubMed ID: 12844132)
1. Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide.
Niemi M; Neuvonen M; Juntti-Patinen L; Backman JT; Neuvonen PJ
Clin Pharmacol Ther; 2003 Jul; 74(1):25-31. PubMed ID: 12844132
[TBL] [Abstract][Full Text] [Related]
2. Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.
Niemi M; Backman JT; Neuvonen M; Laitila J; Neuvonen PJ; Kivistö KT
Clin Pharmacol Ther; 2001 Apr; 69(4):194-200. PubMed ID: 11309547
[TBL] [Abstract][Full Text] [Related]
3. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects.
Niemi M; Backman JT; Neuvonen M; Neuvonen PJ
Br J Clin Pharmacol; 2003 Oct; 56(4):427-32. PubMed ID: 12968988
[TBL] [Abstract][Full Text] [Related]
4. The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol.
Sunkara G; Bigler H; Wang Y; Smith H; Prasad P; McLeod J; Ligueros-Saylan M
Curr Med Res Opin; 2004 Jan; 20(1):41-8. PubMed ID: 14741071
[TBL] [Abstract][Full Text] [Related]
5. Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide.
Niemi M; Backman JT; Juntti-Patinen L; Neuvonen M; Neuvonen PJ
Br J Clin Pharmacol; 2005 Aug; 60(2):208-17. PubMed ID: 16042675
[TBL] [Abstract][Full Text] [Related]
6. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone.
Jaakkola T; Backman JT; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2005 May; 77(5):404-14. PubMed ID: 15900286
[TBL] [Abstract][Full Text] [Related]
7. Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction.
Granfors MT; Backman JT; Neuvonen M; Ahonen J; Neuvonen PJ
Clin Pharmacol Ther; 2004 Apr; 75(4):331-41. PubMed ID: 15060511
[TBL] [Abstract][Full Text] [Related]
8. The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects.
Niemi M; Kajosaari LI; Neuvonen M; Backman JT; Neuvonen PJ
Br J Clin Pharmacol; 2004 Apr; 57(4):441-7. PubMed ID: 15025742
[TBL] [Abstract][Full Text] [Related]
9. Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide.
Park JY; Kim KA; Park PW; Park CW; Shin JG
Clin Pharmacol Ther; 2003 Oct; 74(4):334-40. PubMed ID: 14534520
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and metabolism of nateglinide in humans.
Weaver ML; Orwig BA; Rodriguez LC; Graham ED; Chin JA; Shapiro MJ; McLeod JF; Mangold JB
Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):415-21. PubMed ID: 11259325
[TBL] [Abstract][Full Text] [Related]
11. Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone.
Niemi M; Backman JT; Neuvonen PJ
Clin Pharmacol Ther; 2004 Sep; 76(3):239-49. PubMed ID: 15371985
[TBL] [Abstract][Full Text] [Related]
12. Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.
Kalliokoski A; Backman JT; Neuvonen PJ; Niemi M
Pharmacogenet Genomics; 2008 Nov; 18(11):937-42. PubMed ID: 18854776
[TBL] [Abstract][Full Text] [Related]
13. Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.
Kalliokoski A; Neuvonen M; Neuvonen PJ; Niemi M
J Clin Pharmacol; 2008 Mar; 48(3):311-21. PubMed ID: 18187595
[TBL] [Abstract][Full Text] [Related]
14. The effect of nateglinide taken with food on gastric emptying rates in healthy subjects.
Anderson D; Shelley S; Kellett N; Marshall D; Nimmo W
Clin Ther; 2003 Jun; 25(6):1722-38. PubMed ID: 12860494
[TBL] [Abstract][Full Text] [Related]
15. Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers.
Cheng Y; Wang G; Zhang W; Fan L; Chen Y; Zhou HH
Eur J Clin Pharmacol; 2013 Mar; 69(3):407-13. PubMed ID: 22842957
[TBL] [Abstract][Full Text] [Related]
16. A single dose of nateglinide improves post-challenge glucose metabolism and endothelial dysfunction in Type 2 diabetic patients.
Shimabukuro M; Higa N; Takasu N; Tagawa T; Ueda S
Diabet Med; 2004 Sep; 21(9):983-6. PubMed ID: 15317602
[TBL] [Abstract][Full Text] [Related]
17. Effect of a selective CYP2C9 inhibitor on the pharmacokinetics of nateglinide in healthy subjects.
Sabia H; Sunkara G; Ligueros-Saylan M; Wang Y; Smith H; McLeod J; Prasad P
Eur J Clin Pharmacol; 2004 Aug; 60(6):407-12. PubMed ID: 15197517
[TBL] [Abstract][Full Text] [Related]
18. Effects of timing of administration and meal composition on the pharmacokinetic and pharmacodynamic characteristics of the short-acting oral hypoglycemic agent nateglinide in healthy subjects.
Luzio SD; Anderson DM; Owens DR
J Clin Endocrinol Metab; 2001 Oct; 86(10):4874-80. PubMed ID: 11600556
[TBL] [Abstract][Full Text] [Related]
19. Insulin glargine in combination with nateglinide in people with Type 2 diabetes: a randomized placebo-controlled trial.
Dashora UK; Sibal L; Ashwell SG; Home PD
Diabet Med; 2007 Apr; 24(4):344-9. PubMed ID: 17298589
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]